Amgen Inc.
Moat Score — Amgen Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Amgen holds extensive patent portfolios and regulatory exclusivity on complex biologics, along with deep physician trust and prescribing relationships built over decades as a biotech pioneer. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Amgen's large-scale biologics manufacturing infrastructure provides some cost efficiency, but it is not a low-cost producer relative to peers, and biosimilar competitors are increasingly undercutting it on price. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Historic pricing power on patent-protected biologics remains real but is eroding under IRA drug-price negotiation, payer rebate pressure, and biosimilar competition on legacy products like Enbrel and Prolia. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products carry no network effect — value to one patient or physician does not increase as more people use the drug. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients have some inertia around established therapies and treatment protocols, but this is modest compared to true switching costs and evaporates quickly once biosimilars or superior alternatives are approved. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Large-scale biologics R&D, manufacturing, and global regulatory/commercial infrastructure require enormous capital and time to replicate, creating real barriers to entry even though many large biopharma competitors already exist. |